🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, Ipilimumab, Sutent 12.5 mg hard capsules, Sutent 12.5 mg hard capsules

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or Metastatic Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  2. Irinotecan Accord, 20 mg/ml, koncentrat do sporządzania roztworu do infuzji, Bendadocel 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cyramza 10 mg/ml concentrate for solution for

    AstraZeneca AB

    Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

    phase 3 small molecule active

    1 trial

  3. Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung, Calciumfolinat Sandoz 10 mg/ml – Injektions-/Infusionslösung, SANIFOLIN polvere per soluzione iniettabile, Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Paclitaxel Accord 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, Cyramza 10 mg/ml c

    The George Institute

    advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctions, who failed prior line of palliative chemotherpay

    phase 3 small molecule active

    1 trial

  4. Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers)

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation

    phase 3 small molecule completed

    1 trial

  5. Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, C1-esterase inhibitor

    Maze Therapeutics

    acute hereditary angioedema attacks

    phase 3 small molecule active

    1 trial

  6. Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, Panzyga 100 mg/ml Infusionslösung

    Maze Therapeutics

    Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia.

    phase 3 small molecule active

    1 trial

  7. Isotone Natriumchloridlösung 0,9 % Braun Injektionslösung, JNJ-80202135, JNJ-80202135

    Janssen-Cilag International N.V.

    Warm Autoimmune Hemolytic Anemia

    phase 3 small molecule active

    1 trial

  8. Ivabradine Anpharm 5 mg film-coated tablets, Placebo: lactose monohydrate, microcrystalline cellulose, native corn starch, colloidal anhydrous silica, maltodextrin, magnesium stearate Capsule: Beef gelatin, Glycerol, Titanium dioxide

    COLLEGIUM PHARMACEUTICAL, INC

    Myocardial Injury after Noncardiac Surgery

    phase 3 small molecule active

    1 trial

  9. Ivonescimab Injection

    Summit Therapeutics

    Non-Small Cell Lung Cancer

    phase 3 mab active

    2 trials

  10. Ixazomib, thalidomide, & dexamethasone (ITD) re-induction

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  11. JEMPERLI 500 mg concentrate for solution for infusion, Docetaxel Hikma 20 mg/1 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 160 mg/8 ml Konzentrat zur Herstellung einer Infusionslösung

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  12. JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Ningbo Cancer Hospital

    Patients with localized prostate cancer and high-risk features of relapse.

    phase 3 small molecule active

    1 trial

  13. JNJ 67896062, Matching Placebo for Macitentan 75 mg, JNJ 67896062, Matching Placebo for Macitentan 37.5 mg, Opsumit 10 mg film-coated tablets, Matching Placebo for Macitentan 10 mg

    Lacuna Pharma Pty Ltd

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  14. JNJ-42756493, GEMCITABINE , MITOMYCIN

    Janssen-Cilag International N.V.

    FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  15. JNJ-54767414

    Janssen-Cilag International N.V.

    Precancerous form of blood cancer in the bone marrow

    phase 3 small molecule active

    1 trial

  16. JNJ-56021927

    Ningbo Cancer Hospital

    High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy.

    phase 3 small molecule active

    1 trial

  17. JNJ-56021927, Prednison acis 5 mg, Tabletten, ZYTIGA 250 mg tablets, placebo to match JNJ-56021927/Apalutamide, -

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  18. JNJ-61186372, Carboplatin 10 mg/ml Intravenous Infusion, CARBOPLATIN , Pemetrexed Seacross 500 mg powder for concentrate for solution for infusion, PEMETREXED

    Janssen-Cilag International N.V.

    EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  19. JNJ-61186372, Erbitux 5 mg/mL solution for infusion, Erbitux 5 mg/mL solution for infusion

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    phase 3 small molecule active

    1 trial

  20. JNJ-61186372, JNJ-73841937, JNJ-61186372

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  21. JNJ-63723283, JNJ-63723283, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., JNJ-17000139, GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Gemcitabine100 mg/ml Concentrate for Solution for Infusion, Gemcitabin Accord 100 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Janssen-Cilag International N.V.

    Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder

    phase 3 small molecule active

    1 trial

  22. JNJ-67896049, JNJ-67896049, Opsumit 10 mg film-coated tablets, JNJ-68150420, JNJ-67896049

    Lacuna Pharma Pty Ltd

    pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  23. JNJ-67896062, JNJ-67896062

    Lacuna Pharma Pty Ltd

    Pediatric pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  24. JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources